Last reviewed · How we verify
AD 452
At a glance
| Generic name | AD 452 |
|---|---|
| Sponsor | Sosei |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine (PHASE1)
- A Multicentre Trial to Determine the Efficacy of AD 452 in RA Subjects. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AD 452 CI brief — competitive landscape report
- AD 452 updates RSS · CI watch RSS
- Sosei portfolio CI